Regeneron will start delivering quarterly dividends 37 years into its existence
Regeneron Pharmaceuticals, one of the original and longest-standing biotech companies, is entering the dividends arena for the first time. The Tarrytown, NY-based drugmaker surprised the market Tuesday...
View ArticleUpdated: Pfizer sticks to 2025 projections as Covid sales stabilize, R&D...
Pfizer’s high-profile, high-volatility Covid-19 franchise stabilized at the end of 2024, as the New York drugmaker pursues a revamp of its R&D operations and continues to cut costs. Pfizer’s Covid...
View ArticleBavarian Nordic’s stock sinks after 2024 revenues underwhelm
Bavarian Nordic’s stock dropped around 10% on the Danish stock exchange Tuesday after reporting disappointing 2024 sales despite a rise of demand for its mpox vaccines. Decreased orders for its public ...
View ArticleStudy using experimental Eli Lilly drug will try to stop Alzheimer’s decades...
Alzheimer’s disease has afflicted Hannah Richardson’s family for generations. A rare genetic mutation, passed down from her great-grandmother, has struck her relatives with the first signs of memory...
View ArticleHow opioid addiction treatment startup Bicycle Health reached a profit
Bicycle Health, a provider of telehealth treatment for opioid use disorder, has hit a major milestone that’s eluded many health tech startups: It turned a profit. The company, based in Boston and...
View ArticleFDA approves Supernus’ Parkinson’s drug-device after two rejections
At long last, the FDA approved Supernus Pharmaceuticals’ Parkinson’s disease treatment, which will be marketed as Onapgo. Onapgo is now approved to treat motor fluctuations in adults with advanced...
View ArticleUpdated: RFK Jr. advances out of Senate committee with Cassidy’s support
Sen. Bill Cassidy (R-LA) voted to advance Robert F. Kennedy Jr.’s nomination for HHS secretary to the full Senate, a key show of support from one of the nominee's most vocal critics on the Republican ...
View ArticleTurnstone stops TIL studies; GH Research’s $150M offering
Plus, news about Auron Therapeutics, Akribion Therapeutics, Enveric Biosciences and Valerio Therapeutics: Turnstone Biologics to discontinue TIL studies, “review strategic alternatives”: The company...
View ArticleIllumina added to China's blacklist following Biosecure Act, tariffs
China added DNA sequencing giant Illumina to a list of blacklisted entities after proposed US legislation targeted two Chinese rivals to Illumina and President Donald Trump imposed a 10% tax on all...
View ArticleTrump undercuts RFK Jr. assurances on vaccines, autism
Robert F. Kennedy Jr. is headed for Senate confirmation following Tuesday’s committee vote and a statement of support from the GOP’s biggest skeptic. But it’s still very, very unclear which Kennedy...
View ArticlePfizer says it has at least $10B available for deals in 2025
Pfizer's next deals are likely to be longer-term efforts to reload its R&D work rather than big-ticket, late-stage assets, the company's top executives said Tuesday. “Looking forward, we are...
View ArticleFDA approves Roche's ocular implant in diabetic macular edema
Roche subsidiary Genentech announced Tuesday that it won FDA approval for its eye implant Susvimo to treat diabetic macular edema, a diabetes complication that causes swelling and blurred vision....
View ArticleJ&J asks court for quick decision in 340B rebate model fight
Johnson & Johnson has asked a federal district court to expedite its decision in a case over the company’s proposed 340B rebate model, citing upcoming deadlines for complying with the Inflation...
View ArticleAmgen announces hold on Phase 1 obesity candidate, pipeline cuts
Amgen said one of its early-stage obesity programs has been put on a clinical hold by the FDA, while reiterating its ambitions to become a major player in the crowded field. The company hasn’t revealed...
View ArticleUpdated: Novo Nordisk sees growth slowing this year, plans CagriSema filing...
Novo Nordisk had a good 2024, but this year might be less stellar. The Danish company’s 2024 sales increased 26% from the year before at constant currency, it said Wednesday, but ...
View ArticleGSK defiant against vaccine challenges, will prioritize other growth areas
GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, which saw full-year 2024 sales slide from the year prior. The drop was...
View ArticleWith first drug now in the clinic, Alys eyes megaround for rest of pipeline
Alys Pharmaceuticals is on the hunt for a large financing to carry forward its pipeline — an amalgamation of six Medicxi startups — following the clearance of its first clinical trial this week ...
View ArticleEyePoint shares more mid-stage data for therapy trying to compete with...
EyePoint Pharmaceuticals, a biotech attempting to grab a sliver of Regeneron's share of the degenerative eye disease market, said six-month results show its drug met the primary endpoint in a Phase 2...
View ArticleBristol Myers, Kyowa Kirin disclose layoffs
Bristol Myers Squibb lays off 67 staffers in NJ: The company is letting go of 67 workers in Lawrence Township between April and December, according to a New Jersey WARN Notice ...
View Article